Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash & Current Investments (2019 - 2026)

Alx Oncology Holdings' Cash & Current Investments history spans 5 years, with the latest figure at $182.7 million for Q4 2023.

  • On a quarterly basis, Cash & Current Investments fell 31.36% to $182.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $182.7 million, a 31.36% decrease, with the full-year FY2023 number at $182.7 million, down 31.36% from a year prior.
  • Cash & Current Investments hit $182.7 million in Q4 2023 for Alx Oncology Holdings, down from $190.0 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for ALXO hit a ceiling of $434.2 million in Q4 2020 and a floor of $9.0 million in Q4 2019.
  • Historically, Cash & Current Investments has averaged $274.0 million across 5 years, with a median of $275.6 million in 2022.
  • Biggest five-year swings in Cash & Current Investments: soared 4715.56% in 2020 and later tumbled 33.31% in 2023.
  • Tracing ALXO's Cash & Current Investments over 5 years: stood at $9.0 million in 2019, then soared by 4715.56% to $434.2 million in 2020, then decreased by 16.25% to $363.7 million in 2021, then fell by 26.8% to $266.2 million in 2022, then tumbled by 31.36% to $182.7 million in 2023.
  • Business Quant data shows Cash & Current Investments for ALXO at $182.7 million in Q4 2023, $190.0 million in Q3 2023, and $212.8 million in Q2 2023.